Core Viewpoint - The announcement indicates a significant reduction in shareholding by the controlling shareholder and an investment management partnership, which may impact the company's governance and market perception [1] Shareholding Changes - The controlling shareholder, Shi Huiyong, reduced his holdings by 4,402,400 shares, decreasing his ownership from 50.27% to 48.27% [1] - Taizhou Jincheng Investment Management Partnership reduced its holdings by 2,204,840 shares, lowering its stake from 6.47% to 5.47% [1] - Following these transactions, the combined shareholding of Shi Huiyong, Jincheng Investment, and their concerted parties decreased from 63.96% to 61.21%, marking a change that touches the 1% threshold [1]

Core Viewpoint - The stock price of Gongdong Medical (605369) has shown a slight increase, closing at 19.62 yuan, while the company faces challenges with a significant drop in net profit for the third quarter of 2025 compared to the previous year [1][4]. Shareholder Changes - On October 31, Gongdong Medical announced that shareholder Taizhou Jincheng Investment Management Partnership (Limited Partnership) reduced its holdings by 540,200 shares from October 9 to October 30, decreasing its ownership from 6.47% to 6.22% [2][5]. - As of September 30, the number of shareholders reached 11,600, an increase of 1,734 shareholders or 17.57% compared to June 30 [3][6]. Financial Performance - Gongdong Medical's Q3 2025 report indicates a total revenue of 845 million yuan for the first three quarters, reflecting a year-on-year increase of 1.08%. However, the net profit attributable to shareholders dropped by 49.1% to 71.96 million yuan [4][6]. - In Q3 alone, the company reported a revenue of 288 million yuan, up 2.07% year-on-year, but the net profit fell by 53.12% to 21.62 million yuan [4].

Core Viewpoint - Gongdong Medical is a leading manufacturer of disposable medical consumables in China, with advanced production technology and strict quality control systems [1] Group 1: Business Overview - Gongdong Medical was established on August 17, 2009, and was listed on the Shanghai Stock Exchange on September 16, 2020 [1] - The company focuses on the research, production, and sales of disposable medical consumables, categorized under the pharmaceutical and biological industry, specifically in medical devices and consumables [1] Group 2: Financial Performance - For Q3 2025, Gongdong Medical reported revenue of 845 million, ranking 23rd among 50 companies in the industry [2] - The industry leader, Yingke Medical, reported revenue of 7.425 billion, while the second, Guoke Hengtai, reported 5.353 billion; the industry average revenue was 1.379 billion, and the median was 755 million [2] - The company's net profit for the same period was 71.89 million, ranking 29th in the industry [2] - The top net profit earners were Lepu Medical at 999.6 million and Yingke Medical at 952 million, with the industry average at 183 million and the median at 75.88 million [2] Group 3: Financial Ratios - As of Q3 2025, Gongdong Medical's debt-to-asset ratio was 18.49%, an increase from 15.66% year-on-year, which is lower than the industry average of 23.66%, indicating good solvency [3] - The company's gross profit margin for Q3 2025 was 30.13%, down from 33.35% year-on-year, and below the industry average of 48.78%, suggesting a need for improvement in profitability [3] Group 4: Executive Compensation - The chairman, Shi Huiyong, received a salary of 749,000 for 2024, an increase of 68,600 from 2023 [4] - The general manager, Zhong Weifeng, earned 646,900 in 2024, up by 62,300 from the previous year [4] Group 5: Shareholder Information - As of September 30, 2025, the number of A-share shareholders for Gongdong Medical increased by 17.57% to 11,600 [5] - The average number of circulating A-shares held per shareholder decreased by 14.94% to 19,000 [5]

本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少☑ | | --- | --- | --- | --- | | 权益变动前合计比例 | 64.21% | | | | 权益变动后合计比例 | 63.96% | | | | 本次变动是否违反已作出的承诺、 意向、计划 | 是□ | 否☑ | | | 是否触发强制要约收购义务 | 是□ | 否☑ | | 一、 信息披露义务人及其一致行动人的基本信息 1、身份类别 | | ☑控股股东/实际控制人及其一致行动人 | | --- | --- | | | □其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用于无控 | | | 股股东、实际控制人） | | | □其他______________（请注明） | 证券代码：605369 证券简称：拱东医疗 公告编号：2025-035 浙江拱东医疗器械股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的 提示性公告 浙江拱东医疗器械股份有限公司（以下简称"公司"、"拱东医 ...

Core Points - Gongdong Medical (605369.SH) announced a share reduction by its shareholder, Jinch Investment, which sold 540,240 shares through centralized bidding from October 9 to October 30, 2025 [1] - Following this transaction, Jinch Investment and its concerted parties reduced their total shareholding from 141,558,049 shares to 141,017,809 shares, decreasing their ownership percentage from 64.21% to 63.96%, marking a change that touches the 1% threshold [1]

Core Viewpoint - Gongdong Medical announced a share reduction plan by its shareholder Taizhou Jinch Investment Management Partnership, which will not affect the company's control [1] Summary by Relevant Sections - **Share Reduction Details** - From October 9 to 30, 2025, Taizhou Jinch Investment Management Partnership will reduce its holdings by 540,240 shares through centralized bidding [1] - After this change, the total shares held by Jinch Investment and its concerted parties will decrease from 141,558,049 shares to 141,017,809 shares [1] - The shareholding percentage will drop from 64.21% to 63.96%, reaching a 1% threshold [1] - **Impact on Company Control** - The reduction is part of a planned divestment and does not trigger a mandatory takeover bid [1] - The company's controlling stake remains unaffected, and the reduction plan is not yet fully implemented [1]

Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, and assumes legal responsibility for any false records or misleading statements [2][3][8] Financial Data - The third quarter financial report for 2025 was approved by the company's board of directors and audit committee, with no objections or abstentions [3] - The financial statements are unaudited, and the report period refers to the three months from the beginning to the end of the quarter [4][7] Non-Recurring Gains and Losses - The company has identified non-recurring gains and losses, but specific amounts and reasons for classification are not detailed in the provided documents [5] Shareholder Information - Information regarding the total number of common shareholders and the top ten shareholders is mentioned, but specific details are not provided in the documents [6]

Group 1 - The core viewpoint of the news is that Gongdong Medical reported its third-quarter performance, showing a slight increase in revenue but a significant decrease in net profit [1] Group 2 - Gongdong Medical's revenue for the first three quarters of 2025 is approximately 845 million yuan, representing a year-on-year increase of 1.08% [1] - The net profit attributable to shareholders of the listed company is approximately 71.96 million yuan, reflecting a year-on-year decrease of 49.1% [1] - As of the report date, Gongdong Medical's market capitalization is 4.2 billion yuan [2]

Core Viewpoint - Gongdong Medical (605369.SH) reported a total operating revenue of 845 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 1.08% [1] - The net profit attributable to shareholders decreased by 49.1% to 71.96 million yuan, with basic earnings per share at 0.33 yuan [1] Financial Performance - Total operating revenue for the first three quarters reached 845 million yuan, showing a slight increase of 1.08% compared to the previous year [1] - Net profit attributable to the parent company's shareholders was 71.96 million yuan, marking a significant decline of 49.1% year-on-year [1] - Basic earnings per share stood at 0.33 yuan [1]

Financial Performance - The company's operating revenue for the third quarter was CNY 288,161,548.30, representing a year-on-year increase of 2.07%[5] - The total profit for the quarter was CNY 23,240,171.71, showing a significant decrease of 54.42% compared to the same period last year[6] - The net profit attributable to shareholders was CNY 21,615,278.21, down 53.12% year-on-year[6] - The basic earnings per share for the quarter was CNY 0.10, a decrease of 52.38% compared to the previous year[6] - The company experienced a 49.97% decline in total profit for the year-to-date compared to the same period last year[10] - Net profit for the first three quarters of 2025 was ¥71,890,298.22, down from ¥141,382,840.75 in 2024, indicating a decline of approximately 49.1%[22] - The company experienced a decrease in total comprehensive income to ¥66,810,834.59 from ¥135,771,968.77, a decline of approximately 50.8% year-over-year[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,127,116,445.47, an increase of 9.01% from the end of the previous year[6] - Current assets as of September 30, 2025, totaled RMB 1,102,686,133.56, up from RMB 865,266,163.55 at the end of 2024, indicating a significant increase in liquidity[16] - Total liabilities as of September 30, 2025, amounted to RMB 393,205,904.63, compared to RMB 233,788,763.79 at the end of 2024, indicating a significant rise in financial obligations[18] - The company's total assets reached RMB 2,127,116,445.47, up from RMB 1,951,340,242.04, reflecting a growth of approximately 9%[18] - Non-current assets decreased to RMB 1,024,430,311.91 from RMB 1,086,074,078.49, indicating a decline of about 5.7%[17] Cash Flow - The company's cash flow from operating activities for the year-to-date was CNY 149,044,625.16, reflecting a 2.38% increase[6] - The net cash flow from operating activities was ¥149,044,625.16, compared to ¥145,584,021.87 in the previous year, showing a slight increase of about 3.18%[26] - Cash and cash equivalents increased to RMB 507,913,240.40 from RMB 303,188,874.77, reflecting a growth of approximately 67.5%[16] - Cash and cash equivalents at the end of the period totaled ¥507,913,240.40, up from ¥502,874,015.62 at the end of the same period last year, reflecting a growth of approximately 1.04%[27] - The company reported a net cash outflow from investing activities of ¥42,246,685.27, compared to a net outflow of ¥30,209,819.55 in the previous year, indicating an increase in investment expenditures[27] - Cash inflow from financing activities was ¥247,132,128.00, significantly higher than ¥70,500,000.00 in the same period of 2024, representing an increase of approximately 250.5%[27] Shareholder Information - The company has a total of 11,604 common shareholders at the end of the reporting period[12] - The company reported a total of 10 major shareholders, with the largest holding 110,836,040 shares, representing a significant concentration of ownership[14] Operating Costs - Total operating costs increased to ¥752,127,483.02 from ¥683,540,594.88, marking a rise of about 10.05% year-over-year[22] Tax Expenses - The company’s tax expenses for the period were ¥7,204,990.44, down from ¥16,726,505.45 in the previous year, indicating a decrease of about 56.9%[22]